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Metabolic, gastrointestinal, and CNS neuropeptide effects of
brain leptin administration in the rat. Am. J. Physiol. 276
(Regulatory Integrative Comp. Physiol. 45): R1425–R1433,
1999.—To investigate whether brain leptin involves neuropep-
tidergic pathways influencing ingestion, metabolism, and
gastrointestinal functioning, leptin (3.5 µg) was infused daily
into the third cerebral ventricular of rats for 3 days. To
distinguish between direct leptin effects and those secondary
to leptin-induced anorexia, we studied vehicle-infused rats
with food available ad libitum and those that were pair-fed to
leptin-treated animals. Although body weight was compara-
bly reduced (28%) and plasma glycerol was comparably
increased (142 and 17%, respectively) in leptin-treated and
pair-fed animals relative to controls, increases in plasma
fatty acids and ketones were only detected (132 and 234%,
respectively) in pair-fed rats. Resting energy expenditure
(215%) and gastrointestinal fill (250%) were reduced by
pair-feeding relative to the ad libitum group, but they were
not reduced by leptin treatment. Relative to controls, leptin
increased hypothalamic mRNA for corticotropin-releasing
hormone (CRH; 61%) and for proopiomelanocortin (POMC;
31%) but did not reduce mRNA for neuropeptide Y. These
results suggest that CNS leptin prevents metabolic/gastroin-
testinal responses to caloric restriction by activating hypotha-
lamic CRH- and POMC-containing pathways and raise the
possibility that these peripheral responses to CNS leptin
administration contribute to leptin’s anorexigenic action.
OB protein; sympathetic nervous system; corticotropin-
releasing hormone; proopiomelanocortin; food intake
EVIDENCE SUGGESTS that food intake and body adiposity
are controlled, in part, by hormones that modulate
neuropeptides within areas in the central nervous
system (CNS) that are involved in the regulation of
eating behavior. After its discovery by Zhang et. al. (60)
in 1994, attention has focused on leptin (also named OB
protein), the 167-amino acid protein product of the ob
gene that is mainly synthesized in adipose tissue and
secreted in proportion to body adiposity (e.g., 11, 31, 44,
52). Leptin gains access to the CNS, apparently via a
receptor-mediated transport system (2, 44), where it
interacts with neuronal leptin receptors in brain areas
that are involved in the control of ingestive behavior
(e.g., 10, 45, 57). A central site of action is suggested by
the observation that administration of relatively low
doses of leptin into the CNS causes a reduction of food
intake and body weight (e.g., 9, 13, 49) without produc-
ing incapacitation or malaise (55).
Body adiposity is affected not only by changes in food
intake, but also by changes in energy metabolism.
Accordingly, leptin also affects fuel metabolism, includ-
ing metabolic rate, thermogenesis, cellular fat oxida-
tion, and glucose turnover (16, 21, 25, 26, 32, 34, 42, 51,
61). Although direct effects of leptin on peripheral
tissue have been reported (51, 61), alterations in meta-
bolic processes may also result from leptin effects in the
CNS (8). Hence, central leptin administration influ-
ences the synthesis and/or release of CNS peptides,
such as neuropeptide Y (NPY) and corticotropin-
releasing hormone (CRH) (4, 23, 24, 37, 43, 45), that
regulate autonomic outflow. However, many studies
investigating the effect of central leptin on CNS neuro-
peptides involved in regulation of autonomic outflow
were either performed using 1) fasting animals to
circumvent leptin’s effect on food intake or 2) leptin-
deficient rodents (e.g., ob/ob mice) that display super-
sensitivity to exogenous leptin. To investigate the role
of central leptin in the control of peripheral metabolism
and hypothalamic neuropeptides in normal lean (non-
fasting and nonleptin deficient) rats, we injected leptin
into the third cerebral ventricle (i3vt) over a 3-day
period and then measured a variety of metabolic param-
eters [oxygen consumption (VO2), carbon dioxide produc-
tion (VCO2)], circulating levels of fuels and hormones,
hepatic glycogen content, body adiposity, gastrointesti-
nal fill, and hypothalamic gene expression of several
neuropeptides that respond to changes in energy bal-
ance and that regulate neuroendocrine outflow and
metabolism [NPY, CRH, and proopiomelanocortin
(POMC)]. To distinguish between the metabolic, neural
and gastrointestinal effects of intracerebroventricular
leptin and those that are secondary to the decrease in
The costs of publication of this article were defrayed in part by the
payment of page charges. The article must therefore be hereby
marked ‘‘advertisement’’ in accordance with 18 U.S.C. Section 1734
solely to indicate this fact.










food intake resulting from leptin treatment, rats given
central leptin were compared with vehicle-treated rats
that had food available ad libitum and rats that were
pair-fed to the leptin-treated animals. The results
confirm other studies showing that leptin reduces
circulating levels of free fatty acids and ketones, in-
creases fat oxidation (Fat-ox), and prevents the fall in
resting energy expenditure (EE) that normally occurs
with reduced caloric intake. In addition, relative to
pair-fed animals, leptin increased gastrointestinal fill
to the level found in ad libitum-fed controls. Here we
show that these effects can be mediated by leptin acting
in the CNS and suggest that they may, in part, be
explained by leptin-mediated increases in hypotha-
lamic CRH and/or POMC gene expression.
MATERIAL AND METHODS
Animal preparation. Twenty-seven male Long-Evans rats
obtained from the breeding colony maintained by the Depart-
ment of Psychology of the University of Washington were
housed individually in a temperature-controlled environment
(22°C) in stainless steel hanging cages and maintained on a
12:12-h light-dark cycle. All procedures were performed in
accordance with guidelines for animal use at the University of
Washington. Pelleted chow and water were available ad
libitum (except where noted). Under Equithesin anesthesia,
the animals were implanted with 21-gauge stainless steel
cannulas (Plastic One, Roanoke, VA) aimed at the third
ventricle, according to techniques described elsewhere (57).
The cannulas were fitted with removable obturators that
extended 0.5 mm beyond the tip of the guide cannulas. After
surgery, each rat was given 0.15 ml Chloromycetin (100
mg/ml sc) and Gentamicin (40 mg/ml ip) prophylactically. One
week after surgery, cannula placements were confirmed by
administration of 10 ng angiotensin II in 1 µl of saline. Animals
that did not drink 5 ml of water within 60 min were not used (n 5
3). Rats were allowed to recover for at least an additional 2
wk, during which time they were handled twice daily for
adaptation to the experimental procedures. All rats had
returned to above presurgical weights by the time of testing.
Assessment of food consumption and body weight. On 3
consecutive days, freely feeding rats (n 5 8) received an
infusion (over 1 min) of 3.5 µg human leptin dissolved in 3.5 µl
synthetic cerebrospinal fluid (sCSF) i3vt 2 h before the onset
of the dark phase. Human leptin was chosen because this
allowed us to identify unwanted leakage of i3vt-administered
leptin to the periphery (by analysis of human and rat leptin
levels in plasma with specific RIAs sensitive to either form of
leptin). Hence, absence of human leptin in plasma (or at least
nondetectable) argues against the possibility that the periph-
eral effects of i3vt leptin are mediated by a direct peripheral
action of the hormone. Leptin (at least 90% pure) was
harvested from an expression system in which recombinant
DNA of the human gene was overexpressed in Escherichia
coli (for details, see Ref. 8). Food intake and body weight of
these and all other rats included in the present experiments
were assessed daily starting 1 wk before infusions until the
end of the 3-day treatment period. I3vt administration of the
vehicle (sCSF alone) was given to rats that either had food ad
libitum (ad libitum/sCSF; n 5 8) or that were given the same
amount of food as consumed by the leptin-treated rats on each
day (pair-fed/sCSF; n 5 8). The pair-feeding procedure con-
sisted of matching (on the basis of identical body weights,
within 2 g, at the start of i3vt treatments) of eight sCSF-
treated animals to eight leptin-treated animals. On each
sCSF treatment day, half the amount of food that was
consumed by a leptin-treated rat on that day was provided at
the onset of the dark phase, whereas the other half was given
after 4 h in the dark phase, except for the final treatment day.
On that day, half the food was given after 3 h into the dark
phase and the other half 3 h later.
Indirect calorimetry and behavioral assessment. Immedi-
ately after i3vt infusion on the last day of the 3-day treatment
period, animals were placed in an indirect calorimeter cham-
ber (Oxyeco, Columbus Instruments) until 3 h into the dark
phase with access to water only. As soon as the lights went off,
VO2 and carbon dioxide production (VCO2) were assessed. EE
and carbohydrate oxidation (CHO-ox) and Fat-ox were deter-
mined from VO2 and VCO2 using the equations of Ferranini
(18). During gas exchange measurements, behavior of the
animals was recorded and later assessed by an investigator
who was blind to the treatments. Each minute, the behavior
of animals was assigned as ‘‘grooming’’ (whenever an animal
groomed during that minute), ‘‘resting’’ (if an animal was
lying motionless on the cage floor throughout the whole
minute), or ‘‘alertness’’ (when assigned neither grooming nor
resting). Assessment of behavior allowed distinction between
the indirect calorimetry data under resting and nonresting
conditions. For analyses of indirect calorimetry data, we
assumed (on the basis of our unpublished observations of the
relationship between behavior and VO2) that animals ap-
proached a stable resting metabolic state when they dis-
played ongoing resting behavior for at least 15 min after
grooming and for at least 5 min after alertness. Directly after
the 3-h period in the calorimeter, animals were transported
back to their home cage, where they were allowed to feed.
Blood and tissue collection and analyses. The following
morning (1 h after lights on), animals were taken from their
home cages and, within 2 min after opening their cages, were
anesthetized by brief exposure to CO2 and decapitated.
Immediately thereafter, brains and liver samples were taken
and frozen (280°C) and trunk blood was collected in cooled
(0°C) heparinized borosilicate tubes. Brains, liver tissue, and
plasma (after centrifugation for 10 min at 1,500 g, 4°C,
separation into different vials) were stored at 280°C until
analyses. Carcasses were eviscerated and stored at 220°C.
Weights of whole livers, intestines (from stomach to the distal
rectum), and retroperitoneal fat pads were assessed and also
stored at 220°C. Gastrointestinal fill was assessed from the
weight difference of the intestines with and without its
contents. Plasma glucose, triglycerides, and free fatty acids
were assayed using commercial kits (Sigma 510-DA, Sigma
337-B, and Waco, respectively). Total plasma ketone bodies
(acetoacetate plus hydroxy butyrate) and glycerol were mea-
sured using enzymatic procedures with fluorometric detec-
tion (38). Sensitive RIAs assessed the plasma level of human
leptin (Linco; containing antibodies to human leptin without
cross-reactivity to rodent leptin), rat leptin (Linco; containing
antibodies to mouse and rat leptin without cross-reactivity to
human leptin), insulin (47), and corticosterone. Release of
glucose from liver homogenates incubated with amyloglucosi-
dase was used to calculate liver glycogen. Carcasses and
organs were dried, and fat was extracted according to the
method of Leshner et al. (28). Percentage fat of carcasses and
organs was determined from weight differences before and
after the fat extraction procedure.
In situ hybridization. Coronal sections (14 µm) of frozen rat
brain were cut on a cryostat, mounted on RNase-free slides,
and hybridized using antisense oligonucleotide probes based
on cDNA sequences of rat CRH and NPY or with riboprobes
complementary to mRNA for POMC or the mRNA encoding
for the long-form of the leptin receptor (OB-Rb). The probes
were labeled with [33P]adenosine as described elsewhere (46),










and after hybridization, slides were rinsed under high-
stringency conditions and apposed to X-ray film to generate
autoradiographs, which were analyzed by computerized im-
age analysis (53). Determination of NPY, POMC, and OB-Rb
mRNA levels were made on sections from the midregion of the
rostrocaudal extent of the arcuate hypothalamic nucleus
(Arc) selected by an investigator blind to the study conditions.
Measurements of CRH mRNA used a similar approach on
sections obtained from the paraventricular hypothalamic
nucleus (PVN). All densitometry data were collected by a
technician blind to the conditions. The product of hybridiza-
tion area and density was used as an index of relative mRNA
levels.
Statistical analyses. ANOVA with repeated measures with
three levels (ad libitum/sCSF vs. ad libitum/leptin vs. pair-fed/
sCSF) and four factors (days 0–3) was used for analyses of
body weight and food intake data. Further data analyses
(except hypothalamic mRNA) included standard one-way
ANOVA with three levels (ad libitum/sCSF vs. ad libitum/
leptin vs. pair-fed/sCSF). Post hoc analyses were conducted
only if the ANOVA was significant at the P , 0.05 (2 sided)
level and used Tukey’s highly significant difference test, also
set at P , 0.05.
It was previously observed that food-deprivation reduces
hypothalamic POMC mRNA (46), whereas it increases hypo-
thalamic NPY mRNA (43–46). Because leptin treatment in
the same dose used in the present study partially restores the
expression of mRNA levels of POMC and NPY to levels found
in rats under ad libitum feeding conditions (45, 46) and
increases hypothalamic CRH mRNA (45), we ran planned
comparisons (58) between mRNA levels of ad libitum/sCSF-
treated and pair-fed/sCSF-treated animals (effect of negative
energy balance) and between mRNA levels of leptin-treated
and pair-fed/sCSF-treated animals (effect of leptin).
RESULTS
Food consumption and body weight. Figure 1 shows
food intake (Fig. 1, top) and whole body weight (Fig. 1,
bottom) of 3-day leptin-treated, ad libitum/sCSF-
treated, and pair-fed/sCSF-treated animals. Food in-
take (F6,63 5 37.51; P , 0.0001; for time 3 treatment
interaction) decreased by ,50% over the 3-day treat-
ment period in the leptin-treated and pair-fed animals
compared with the ad libitum/sCSF-treated rats, and
this led to an 8% reduction in body weight after 3 days
in leptin-treated (and pair-fed/sCSF treated) animals
relative to ad libitum/sCSF-treated animals (F6,63 5
18.91; P , 0.0001; for time 3 treatment interaction).
Whole body weights of pair-fed/sCSF-treated animals
were not different from those of leptin-treated animals
(respectively, 447.3 6 5.5 and 447.9 6 7.3 g on the final
treatment day).
Behavior and indirect calorimetry. The relative time
spent on grooming, resting, and alertness of leptin-
treated, ad-libitum/sCSF-treated, and pair-fed/sCSF-
treated animals is shown in Table 1. The different
behaviors were not significantly different among groups.
Table 2 shows indirect calorimetry data of leptin-
treated, ad libitum/sCSF-treated, and pair-fed/sCSF-
treated rats under resting metabolic conditions and
over the entire (i.e., total) 3-h period. Throughout the
3-h period in the calorimeter, animals had between two
and six phases in which they displayed ongoing resting
behavior for at least 15 min after grooming behavior
and 5 min after alertness. Resting levels of VO2 (F2,23 5
5.40; P 5 0.013) and VCO2 (F2,23 5 8.59; P 5 0.002) were,
respectively, 16 and 17% lower in pair-fed/sCSF-treated
rats than in leptin-treated rats. VCO2 was also lower in
pair-fed/sCSF-treated rats (213%) than in ad libitum/
sCSF-treated rats. Over the entire 3-h period, VCO2
(F2,23 5 5.41; P 5 0.013) was lower in the pair-fed/sCSF-
treated group relative to VCO2 in leptin-treated (212%)
as well as in ad libitum/sCSF-treated rats (211%).
Respiratory quotient tended to be lower in both leptin-
treated and pair-fed groups relative to ad libitum
controls, but these differences did not reach statistical
significance.
Blood and tissue analyses. Table 3 shows the plasma
concentrations of hormones, fuels, hepatic glycogen
content, percentage body fat (derived from carcass and
Fig. 1. Effect of daily intracerebroventricular infusions of synthetic
cerebrospinal fluid (sCSF; l; n 5 8) or 3.5 µg of leptin (r; n 5 8) on
food intake (top) and body weight (bottom) over a 3-day period. A
third group of animals received intracerebroventricular infusions of
sCSF, but animals in this group were pair-fed to leptin-treated
animals (dashed line; n 5 8). Statistical significance between ad
libitum/sCSF group and leptin group *P , 0.001 and **P , 0.0001.
Table 1. Percentage of time spent on grooming, resting,








Resting 60.862.0 60.764.3 55.564.4
Grooming 11.362.0 7.561.5 11.961.8
Alertness 27.963.0 31.664.1 32.663.8
Values are means 6 SE in percentage of time (over 3-h period in
indirect calorimeter chamber). Rats received daily intracerebroven-
tricular infusion of synthetic cerebrospinal fluid (Ad Libitum sCSF;
n58) or 3.5 µg of leptin (Ad Libitum/Leptin; n58) or they received
intracerebroventricular infusion of sCSF and were pair-fed to leptin-
treated animals (Pair-Fed/sCSF; n58).










organ fat extraction) of i3vt leptin-treated, ad libitum/
sCSF-treated, and pair-fed/sCSF-treated rats. Relative
to the ad libitum/sCSF group, the leptin-treated ani-
mals and pair-fed animals had lower levels of plasma
leptin (measured with mouse RIA: F2,23 5 16.12; P ,
0.0001; levels of leptin with a human-leptin RIA were
nondetectable), hepatic glycogen content (F2,23 5 8.84;
P 5 0.002), and percentage body fat (F2,23 5 9.54; P 5
0.001). The plasma triglyceride level was lower in
leptin-treated (240%) and pair-fed (265%) rats rela-
tive to the level in ad libitum/sCSF-treated rats (F2,23 5
6.71; P 5 0.006). There was a tendency of percentage
body fat to be lower in leptin-treated rats than in
pair-fed/sCSF-treated rats (P 5 0.08). No treatment
differences were observed in plasma levels of glucose,
corticosterone, or insulin among groups. The plasma
levels of corticosterone are relatively high compared
with those in other studies (e.g., 48). Although repeti-
tive i3vt administration of leptin and/or vehicle is not
necessarily associated with negative side effects (see
Ref. 55), it might be that this procedure has caused
some conditioned (i.e., to the investigator) arousal in
these animals, leading to an elevation of plasma levels
of corticosterone at the time of death. Figure 2 shows
the plasma concentrations of ketones, free fatty acids,
and glycerol of i3vt leptin-treated, ad libitum/sCSF-
treated, and pair-fed/sCSF-treated rats. Relative to ad
libitum-fed controls, the leptin-treated (142%) and pair-
fed animals (171%) had an increased level of plasma
glycerol (F2,23 5 9.44; P 5 0.001). In contrast, plasma
levels of both free fatty acids (F2,23 5 7.83; P 5 0.003)
and ketones (F2,23 5 6.30; P 5 0.007) were only higher
in pair-fed animals (respectively, 132 and 234%), but
not in the leptin-treated animals relative to the levels
in ad libitum controls. Figure 3 shows gastrointestinal
fill of i3vt leptin-treated, ad libitum/sCSF-treated, and
pair-fed/sCSF-treated rats. Relative to pair-fed/sCSF-
treated rats, leptin-treated rats had more than twice
the amount of gastrointestinal fill (F2,23 5 14.53; P 5
0.0001), which was, in fact, undistinguishable from the
gastrointestinal fill in ad libitum/sCSF-treated ani-
mals.
Table 2. VO2, VCO2, and RQ under resting metabolic










VO2 752.5629.1 836.8634.4† 699.0625.5
VCO2 669.8628.8 696.7616.2‡ 576.5617.1*
RQ 0.8960.03 0.8460.03 0.8260.03
Total
VO2 848.5625.7 917.9635.5 830.1616.1
VCO2 748.0631.3 760.0612.9† 667.0616.6*
RQ 0.8860.03 0.8360.03 0.8060.02
Values are means 6 SE; ml·kg21 ·h21 for oxygen consumption
(VO2) and carbon dioxide production (VCO2) and in VCO2/VO2 for
respiratory quotient (RQ). Rats received daily intracerebroventricu-
lar infusion of sCSF (n58) or 3.5 µg of leptin (n58) or they received
intracerebroventricular infusion of sCSF and were pair-fed to leptin-
treated animals (n58). *Statistical significance between ad libitum/
sCSF-treated group and other groups (P,0.05); †,‡statistical signifi-
cance between leptin and pair-fed/sCSF-group (P,0.05 and P,0.01,
respectively).
Table 3. Plasma concentrations of fuel and hormones,









Pl glucose, mM 8.3260.23 8.4460.20 8.5160.16
Pl triglycerides, mM 1.5760.23 0.9360.23* 0.5560.12†
Pl corticosterone,
µg/dl 1.6160.64 2.6360.76 1.4360.45
Pl insulin, µU/ml 81.0611.3 73.7612.7 62.367.4
Pl leptin, ng/ml 4.5960.17 2.0060.44‡ 2.1160.42‡
Hepatic glycogen,
mg/g 75.266.4 38.365.6† 45.267.7†
%Body fat 16.161.3 8.460.9‡ 11.561.6*
Values are means 6 SE. Rats received daily intracerebroventricu-
lar infusion of synthetic cerebrospinal fluid (n58) or 3.5 µg leptin
(n58) or they received intracerebroventricular infusion of sCSF and
were pair-fed to leptin-treated animals (n58). Pl, plasma. *,†,‡Statis-
tical significance between ad libitum/sCSF group and other groups
(P,0.05, P,0.01, and P,0.001, respectively).
Fig. 2. Plasma concentrations of ketones, free fatty acids (FFA), and
glycerol in ad libitum-feeding rats that received daily intracerebroven-
tricular infusion of sCSF (open bars; n 5 8) or 3.5 µg leptin (filled
bars; n 5 8) or rats that received intracerebroventricular infusion of
sCSF and were pair-fed to leptin-treated animals (shaded bars; n 5
8). Statistical significance between ad libitum/sCSF-treated group
and other groups: *P , 0.05 and **P , 0.01. Statistical significance
between leptin and pair-fed group: ††P , 0.01.
Fig. 3. Gastrointestinal fill of ad libitum-feeding rats that received
daily intracerebroventricular infusion of sCSF (open bars; n 5 8) or
3.5 µg leptin (filled bars; n 5 8) or rats that received intracerebroven-
tricular infusion of sCSF and were pair-fed to leptin-treated animals
(shaded bars; n 5 8). Statistical significance between ad libitum/sCSF-
treated group and other groups: *P , 0.001. Statistical significance
between leptin and pair-fed group: †P , 0.001.










EE. Because stored triglycerides in fat tissue is a
metabolically inactive compartment, resting and total
CHO-ox and Fat-ox and resting and total EE of animals
were calculated for lean body masses of animals (by
correcting for the amount of body fat from Table 3). The
relative CHO-ox and Fat-ox of leptin-treated, ad libitum/
sCSF-treated, and pair-fed/sCSF-treated animals are
presented in Table 4. Resting (F2,23 5 3.63; P 5 0.044)
and total (F2,23 5 3.83, P 5 0.038) CHO-ox in ad
libitum/sCSF-treated animals was 45 and 49% higher
than in pair-fed/sCSF-treated animals, respectively,
whereas only resting Fat-ox in the leptin-treated group
was 53% higher than the level in the ad libitum/sCSF
group (F2,23 5 3.94; P 5 0.035). Although EE was not
different among groups over the total 3-h period (5.76 6
0.19, 5.62 6 0.14, and 5.25 6 0.15 W/kg lean mass in
the ad libitum/sCSF-, ad libitum/leptin-, and pair-fed/
sCSF-treated rats, respectively), resting EE in ad libi-
tum/sCSF-treated and leptin-treated animals were
higher (13%) than in pair-fed/sCSF-treated animals
(F2,23 5 5.43; P 5 0.013) (Fig. 4).
In situ hybridization. Figure 5 shows the results of in
situ hybridization (expressed as %expression of mean
value of the ad libitum/sCSF group) of mRNA for CRH
in the PVN and mRNA for NPY, POMC, and the
long-form leptin receptor in the Arc. Expression of
hypothalamic CRH mRNA was increased in leptin-
treated animals compared with ad libitum/sCSF-
treated (63%) and pair-fed/sCSF-treated (58%) rats.
The expression of NPY mRNA in pair-fed/sCSF-treated
animals was 64% higher than the level observed in ad
libitum/sCSF-treated animals (P , 0.05), whereas those
of leptin-treated rats were not significantly different
from ad libitum controls or pair-fed controls. The
expression of POMC mRNA in the Arc was higher (23%)
in leptin-treated animals than in pair-fed/sCSF-treated
animals. The levels of Ob-Rb mRNA in the Arc were not
different among groups.
DISCUSSION
The present study investigated the effect of central
leptin administration on ingestive behavior, energy
metabolism, and the synthesis of hypothalamic neuro-
peptides that respond to changes in energy balance. As
predicted, i3vt leptin administration substantially re-
duced daily food intake (by ,50%) and, over a 3-day
treatment period, resulted in a reduction in body
weight of ,8%. By comparing the results from leptin-
treated rats to those in pair-fed animals, we were able
to distinguish the metabolic and hypothalamic re-
sponses caused by leptin treatment from those that
were secondary to reduced food intake. This approach
identified a number of metabolic and hypothalamic
effects that are directly attributable to leptin action in
the brain.
Some of the metabolic effects of leptin treatment can
be attributed to food restriction. Relative to ad libitum-
fed controls, both the leptin-treated and pair-fed groups
had lower levels of plasma leptin, triglycerides, liver
glycogen, and body fat content and higher levels of
plasma glycerol. By other parameters, however, leptin-
Table 4. CHO-ox and Fat-ox under resting metabolic










CHO-ox 705694 495684 389675*
Fat-ox 121628 260647* 245639
Total
CHO-ox 7646120 524691 391673*
Fat-ox 200644 293651 317633
Values are means 6 SE in mg·kg lean mass21 ·h21. Rats received
daily intracerebroventricular infusion of synthetic cerebrospinal
fluid (n58) or 3.5 µg of leptin (n58), or they received intracerebroven-
tricular infusion of sCSF and were pair-fed to leptin-treated animals
(n58). CHO-ox, carbohydrate oxidation; Fat-ox, fat oxidation. *Sta-
tistical significance between Ad Libitum/sCSF group and other
groups (P,0.05).
Fig. 4. Resting energy expenditure of ad libitum-feeding rats that
received daily intracerebroventricular infusion of sCSF (open bars;
n 5 8) or 3.5 µg leptin (filled bars; n 5 8) or rats that received
intracerebroventricular infusion of sCSF and were pair-fed to leptin-
treated animals (shaded bars; n 5 8). Statistical significance between
ad libitum/sCSF-treated group and other groups: *P ,0.05. Statisti-
cal significance between leptin and pair-fed group: † P , 0.05.
Fig. 5. Expression of mRNA for corticotropin-releasing hormone
(CRH) in parvocellular paraventricular hypothalamus and expres-
sion of mRNAfor neuropeptide Y (NPY), proopiomelanocortin (POMC),
and long-form leptin receptor (OB-Rb) in arcuate hypothalamic
nucleus of ad libitum-feeding rats that received daily intracerebroven-
tricular infusion of sCSF (open bars; n 5 8) or 3.5 µg leptin (filled
bars; n 5 8) or rats that received intracerebroventricular infusion of
sCSF and were pair-fed to leptin-treated animals (shaded bars; n 5
8). Levels of mRNA for CRH, NPY, POMC, and OB-Rb were expressed
as %mean value of ad libitum/sCSF-treated group. Statistical signifi-
cance between ad libitum/sCSF group and other groups: *P , 0.05.
Statistical significance between leptin and food-matched/sCSF-
treated group: †P , 0.05.










treated rats appeared ‘‘fed’’ despite a marked decrease
in food intake. In contrast to pair-fed rats, for example,
leptin-treated rats did not exhibit the increase of
circulating ketone bodies and fatty acids that occurs
when stored triglyceride is hydrolyzed to meet ongoing
energy requirements in the face of inadequate caloric
intake (41). Another characteristic of a state of negative
energy balance is a reduction of basal metabolic rate,
presumably the result of diminished sympathetic tone
(59). We found that whereas pair-fed animals exhibited
a lower resting EE rate at the onset of the dark phase
than was detected in ad libitum-fed controls, resting
EE in leptin-treated animals was well above the level of
the pair-fed animals and, in fact, was indistinguishable
from that in the ad libitum controls. Because there
were no differences in resting, grooming, or alertness,
our data are consistent with previous observations in
ob/ob and lean mice (25, 32) and provide direct support
for the potentially important action (therapeutic, if
shown in humans) of leptin in the brain to prevent the
fall in metabolic rate that accompanies caloric restric-
tion (16).
Because plasma levels of glycerol (a product of triglyc-
eride hydrolysis) were elevated to a similar degree in
leptin-treated and pair-fed animals (respectively, by
143 and 171% relative to ad libitum controls), leptin
treatment did not appear to prevent intracellular break-
down of triglycerides. In fact, consistent with other
reports (e.g., 21, 25, 29, 34), the leptin-treated animals
in the present study, but not pair-fed controls, exhibited
an increase in the rate of total body Fat-ox compared
with the ad libitum group. In addition, the leptin-
treated animals tended to be leaner than their pair-fed
controls. Triglyceride hydrolysis and lipid depletion,
therefore, appeared to be accentuated by central leptin
treatment, and CHO-ox was reduced in pair-fed ani-
mals, but not in the leptin-treated animals, relative to
ad libitum controls. Thus these results suggest that a
combined increase of CHO-ox and Fat-ox contributed to
the relatively high resting EE in leptin-treated rats
relative to pair-fed animals. This picture of increased
EE accompanied by elevated plasma glycerol, but no
increase in plasma free fatty acids and ketone levels,
suggests a unique effect of leptin on CNS pathways that
control metabolism.
The effects of leptin administration on circulating fat
fuels in the present study confirm and extend the
findings of Shimabukuro et al. (51), who, using rats
made hyperleptinemic by adenovirus gene transfer,
hypothesized that leptin increases intracellular Fat-ox
in tissues (i.e., adipose, liver, pancreas, and muscle),
such that lipolysis proceeds without increased plasma
levels of free fatty acids. Whereas others have proposed
that this occurs via a direct effect in peripheral tissues,
our results are the first to demonstrate that these
metabolic responses can be mediated indirectly by an
action of leptin in the brain. The hypothesis that leptin
stimulates intracellular hydrolysis also provides a logi-
cal explanation for reduced plasma ketone body levels
due to reduced availability of circulating free fatty
acids for hepatic ketogenesis. Furthermore, Rossetti et
al. (40) showed that leptin stimulates hepatic gluconeo-
genesis at the expense of glycogenolysis (yielding no net
effect on hepatic glucose output), which potentially
would shunt fatty acids into hepatic b-oxidation and
away from hepatic ketone body formation. This inhibi-
tion of ketogenesis by central leptin provides a poten-
tial mechanism linking fasting-induced reductions in
circulating leptin with the increased ketogenesis re-
ported by Kolaczynski et al. (27).
A number of studies have shown that in addition to
brown adipose tissue, a variety of other peripheral
tissues express mitochondrial uncoupling proteins
(UCP1–3) enabling energy to be shunted into heat (e.g.,
19, 30, 61), and leptin appears to potentiate the synthe-
sis of UCP in most of these tissues (19, 30, 42, 61). It
was shown by Cusin et al. (14) that i3vt leptin treat-
ment over a 4-day period prevents the fall in UCP
mRNA expression that is associated with reduced
caloric intake, demonstrating an effect of CNS leptin on
UCP synthesis. Because a state of negative energy
balance is associated with diminished sympathetic tone
(59) and because leptin has been shown to increase
sympathetic nerve traffic (17, 22), central leptin may
stimulate the expression of UCPs in peripheral tissues
via increased sympathetic outflow, as it does in brown
adipose tissue (12). Thus if central leptin activates both
intracellular fatty acid oxidation and UCP synthesis
within the same peripheral cells, intracellular fatty
acids could provide a substrate for increased thermogen-
esis. This hypothesis intuitively complements the in-
creased glucose turnover reported during both central
and peripheral leptin administration in mice (26).
Chronic leptin administration has been shown in
other studies (21, 29, 34) to augment body weight loss
relative to pair-fed controls. Although weight loss in
leptin-treated animals did not exceed that of pair-fed
controls in our study, this outcome may have been
confounded by the more than twofold increase in the
weight of gastrointestinal fill in the leptin-treated
versus pair-fed groups. Correcting for the weight of
gastrointestinal contents, weight loss of the leptin-
treated rats was 32% greater than that of the pair-fed
groups relative to ad libitum-fed rats. In fact, whereas
leptin-treated rats ate 50% less than ad libitum-fed
controls, the gastrointestinal content weight of these
two groups was indistinguishable. The leptin effects on
gastrointestinal fill are consistent with the findings of
Smedh et al. (54), showing that central leptin adminis-
tration reduces gastric emptying. An inhibitory effect of
leptin on gastrointestinal motility is also supported by
observations in the fa/fa Zucker rat, in which obesity
develops due to a mutation of the leptin receptor (35).
These animals have increased gastric emptying as well
as augmented intestinal transit (33), suggesting that
leptin may normally serve to inhibit gastrointestinal
motility. Inhibition of gastrointestinal motility would
be expected if leptin stimulated sympathetic nervous
system outflow to the gastrointestinal tract as is sug-
gested by the observation that leptin increases overall
sympathetic nerve traffic (17, 22).










To investigate the CNS mechanisms that mediate
leptin’s behavioral, metabolic, and gastrointestinal ef-
fects, we measured hypothalamic mRNA encoding neu-
ropeptides implicated in energy homeostasis. Consis-
tent with our previous studies, we found that central
leptin administration increased CRH mRNA in the
hypothalamic PVN. This effect was not due to reduced
food intake, because pair-fed animals did not show this
response. Because central administration of CRH has
anorexigenic and thermogenic effects (7, 39), the data
in the present and other studies (37, 45) suggest that
leptin’s effects could be mediated through activation of
hypothalamic CRH neurons. This idea is consistent
with a recent study of Uehara et al. (56) demonstrating
that the anorexigenic efficacy of central leptin was
reduced by central administration of a CRH receptor
antagonist. Activation of hypothalamic CRH neurons
could also explain the increased SNS outflow (6) and
thermogenesis (39) that is observed with leptin admin-
istration. It is noteworthy that these stimulatory ef-
fects of leptin on CRH signaling coexist with inhibitory
effects of leptin on the hypothalamic-pituitary axis (23,
24). These paradoxical observations suggest that leptin
may exert distinctly different regulatory effects on
discrete subpopulations of CRH neurons in the PVN.
In addition to leptin effects on CRH mRNA, leptin-
treated animals also had an increased level of POMC
mRNA in the arcuate nucleus relative to the level
observed in pair-fed animals. The increase in hypotha-
lamic POMC gene expression is consistent with what
we observed after central leptin treatment in rats that
were food deprived (46) and supports the hypothesis
that melanocortins, which act centrally to reduce food
intake, are important mediators of leptin signaling
(50).
Previous studies (e.g., Ref. 5) indicate that dramatic
weight loss due to caloric restriction or fasting is
associated with reduced CRH mRNA levels in the PVN,
and this response has been proposed to contribute to
the stimulated feeding behavior and reduced SNS
outflow that occurs in this setting (6). Although food
restriction in the present study was therefore expected
to lower hypothalamic CRH gene expression, we found
no evidence of reduced CRH mRNA in pair-fed animals,
despite weight loss of ,8% relative to ad libitum-fed
controls. This observation suggests that weight loss
must exceed that experienced by pair-fed rats before
CRH mRNA levels are decreased in the PVN (see also
Ref. 48). On the other hand, we did find an increase in
NPY gene expression in the arcuate nucleus of pair-fed
animals relative to ad libitum-fed controls, an effect
that is consistent with previous studies (1, 43, 45, 48).
However, the leptin-treated animals did not have signifi-
cantly reduced levels of NPY mRNA relative to the
pair-fed group. The effect of leptin to reduce hypotha-
lamic NPY gene expression may therefore be detectable
only in animals in which the NPY system has been
activated (e.g., when leptin levels are low). Finally, we
report in the present study that neither leptin treat-
ment nor food restriction significantly affected long-
form leptin receptor mRNA expression in the arcuate
nucleus. Thus, although leptin deficiency in ob/ob mice
is associated with a two- to threefold increase of
expression of leptin receptor mRNA in this brain area
(4), our results do not support the hypothesis that
leptin administration downregulates leptin receptor
gene expression in nonmutant animals with ad libitum
access to food.
Perspectives
Among the many factors capable of reducing food
intake are an increase in the hepatic oxidation of
metabolic fuels, including fat fuels (see Ref. 20), and
gastrointestinal distension (15, 36). The present find-
ings, which show that central leptin administration
increases fuel oxidation and reduces gastrointestinal
clearance, strongly suggest that these metabolic and
gastrointestinal effects of leptin contribute to the an-
orexigenic action of the hormone in the CNS. We
hypothesize that leptin activates sympathetic outflow,
potentially via an increase in hypothalamic CRH signal-
ing, and this response alters substrate metabolism,
metabolic rate, and gastrointestinal function. As shown
in Fig. 6, these peripheral effects, in concert with
changes in hypothalamic effector pathways that act
directly to inhibit food intake, are hypothesized to
produce the sustained negative energy balance and
depletion of body fat stores characteristic of leptin’s
action in the brain.
Fig. 6. Summary model of leptin affecting hypothalamic effector
pathways that act directly to inhibit food intake and, presumably, via
increased sympathetic outflow alter peripheral substrate metabolism
and gastrointestinal functioning (double lines). In turn, these periph-
eral processes elicit feedback signals (dashed lines) that, in concert
with brain leptin’s direct anorexigenic effect, are hypothesized to
sustain negative energy balance and depletion of body fat stores.
CNS, central nervous system; GI, gastrointestinal; ffa, free fatty acid;
WAT, white adipose tissue; BAT, brown adipose tissue; UCP, uncou-
pling protein.
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